Elizabeth M Cespedes Feliciano1, Marilyn L Kwan1, Lawrence H Kushi1, Wendy Y Chen2,3, Erin K Weltzien1, Adrienne L Castillo1, Carol Sweeney4, Philip S Bernard5, Bette J Caan1. 1. Division of Research, Kaiser Permanente Northern California, Oakland, California. 2. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. 4. Utah Cancer Registry, Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 5. School of Medicine, Department of Pathology and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Abstract
BACKGROUND: Studies of obesity and survival among patients with breast cancer produce conflicting results, possibly because of heterogeneity by molecular subtype. METHODS: This study examined whether the association of body mass index (BMI) at diagnosis with breast cancer recurrence and survival varied across subtypes defined by PAM50 (Prediction Analysis of Microarray 50) gene expression. Included were 1559 Kaiser Permanente Northern California members ages 18 to 79 years who had PAM50 assays and were diagnosed with American Joint Committee on Cancer stage I through III breast cancer from 1996 to 2013. Patients reported weight and height. Cox regression models were adjusted for age, menopause, race/ethnicity, stage, and chemotherapy. RESULTS: Over a median of 9 years (maximum, 19 years), 378 women developed recurrent disease, and 312 died from breast cancer. Overall, BMI was not associated with breast cancer recurrence or survival when controlling for subtype (eg, the hazard ratio per 5 kg/m2 of BMI was 1.05 [95% confidence interval, 0.95-1.15] for breast cancer-specific death). However, associations varied by subtype. Among women with luminal A cancers, those who had class II/III obesity, but not class I obesity or overweight, had worse outcomes. When women who had a BMI ≥35 kg/m2 were compared with those who had a BMI from 18.5 to <25 kg/m2 , the hazard ratio was 2.24 (95% confidence interval,1.22-4.11) for breast cancer-specific death and 1.24 (95% confidence interval, 1.00-1.54) for recurrence. There was no association within luminal B, basal-like or human epidermal growth factor over-expressing subtypes. CONCLUSIONS: Among patients who had accurately classified breast cancer subtypes based on gene expression, a BMI ≥35 kg/m2 was adversely associated with outcomes only among those who had luminal A cancers. Research is needed into whether tailoring recommendations for weight management to tumor characteristics will improve outcomes. Cancer 2017;123:2535-42.
BACKGROUND: Studies of obesity and survival among patients with breast cancer produce conflicting results, possibly because of heterogeneity by molecular subtype. METHODS: This study examined whether the association of body mass index (BMI) at diagnosis with breast cancer recurrence and survival varied across subtypes defined by PAM50 (Prediction Analysis of Microarray 50) gene expression. Included were 1559 Kaiser Permanente Northern California members ages 18 to 79 years who had PAM50 assays and were diagnosed with American Joint Committee on Cancer stage I through III breast cancer from 1996 to 2013. Patients reported weight and height. Cox regression models were adjusted for age, menopause, race/ethnicity, stage, and chemotherapy. RESULTS: Over a median of 9 years (maximum, 19 years), 378 women developed recurrent disease, and 312 died from breast cancer. Overall, BMI was not associated with breast cancer recurrence or survival when controlling for subtype (eg, the hazard ratio per 5 kg/m2 of BMI was 1.05 [95% confidence interval, 0.95-1.15] for breast cancer-specific death). However, associations varied by subtype. Among women with luminal A cancers, those who had class II/III obesity, but not class I obesity or overweight, had worse outcomes. When women who had a BMI ≥35 kg/m2 were compared with those who had a BMI from 18.5 to <25 kg/m2 , the hazard ratio was 2.24 (95% confidence interval,1.22-4.11) for breast cancer-specific death and 1.24 (95% confidence interval, 1.00-1.54) for recurrence. There was no association within luminal B, basal-like or humanepidermal growth factor over-expressing subtypes. CONCLUSIONS: Among patients who had accurately classified breast cancer subtypes based on gene expression, a BMI ≥35 kg/m2 was adversely associated with outcomes only among those who had luminal A cancers. Research is needed into whether tailoring recommendations for weight management to tumor characteristics will improve outcomes. Cancer 2017;123:2535-42.
Keywords:
Prediction Analysis of Microarray 50 (PAM50) gene expression assay; body mass index; breast cancer subtype; molecular classification; mortality; obesity; recurrence; survival
Authors: Xuezheng Sun; Hazel B Nichols; Whitney Robinson; Mark E Sherman; Andrew F Olshan; Melissa A Troester Journal: Cancer Causes Control Date: 2015-10-01 Impact factor: 2.506
Authors: Marilyn L Kwan; Christine B Ambrosone; Marion M Lee; Janice Barlow; Sarah E Krathwohl; Isaac Joshua Ergas; Christine H Ashley; Julie R Bittner; Jeanne Darbinian; Keren Stronach; Bette J Caan; Warren Davis; Susan E Kutner; Charles P Quesenberry; Carol P Somkin; Barbara Sternfeld; John K Wiencke; Shichun Zheng; Lawrence H Kushi Journal: Cancer Causes Control Date: 2008-05-14 Impact factor: 2.506
Authors: Ronny Mowad; Quyen D Chu; Benjamin D L Li; Gary V Burton; Frederico L Ampil; Roger H Kim Journal: J Surg Res Date: 2013-06-02 Impact factor: 2.192
Authors: Barbara Sternfeld; Erin Weltzien; Charles P Quesenberry; Adrienne L Castillo; Marilyn Kwan; Martha L Slattery; Bette J Caan Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Marilyn L Kwan; Candyce H Kroenke; Carol Sweeney; Philip S Bernard; Erin K Weltzien; Adrienne Castillo; Rachel E Factor; Kaylynn S Maxfield; Inge J Stijleman; Lawrence H Kushi; Charles P Quesenberry; Laurel A Habel; Bette J Caan Journal: BMC Cancer Date: 2015-04-14 Impact factor: 4.430
Authors: Janie M Lee; Linn Abraham; Diana L Lam; Diana S M Buist; Karla Kerlikowske; Diana L Miglioretti; Nehmat Houssami; Constance D Lehman; Louise M Henderson; Rebecca A Hubbard Journal: J Clin Oncol Date: 2018-05-02 Impact factor: 44.544
Authors: Anna Morra; Audrey Y Jung; Marjanka K Schmidt; Jenny Chang-Claude; Sabine Behrens; Renske Keeman; Thomas U Ahearn; Hoda Anton-Culver; Volker Arndt; Annelie Augustinsson; Päivi K Auvinen; Laura E Beane Freeman; Heiko Becher; Matthias W Beckmann; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Hermann Brenner; Ignacio Briceno; Sara Y Brucker; Nicola J Camp; Daniele Campa; Federico Canzian; Jose E Castelao; Stephen J Chanock; Ji-Yeob Choi; Christine L Clarke; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Thilo Dörk; Alison M Dunning; Miriam Dwek; Douglas F Easton; Diana M Eccles; Kathleen M Egan; D Gareth Evans; Peter A Fasching; Henrik Flyger; Manuela Gago-Dominguez; Susan M Gapstur; José A García-Sáenz; Mia M Gaudet; Graham G Giles; Mervi Grip; Pascal Guénel; Christopher A Haiman; Niclas Håkansson; Per Hall; Ute Hamann; Sileny N Han; Steven N Hart; Mikael Hartman; Jane S Heyworth; Reiner Hoppe; John L Hopper; David J Hunter; Hidemi Ito; Agnes Jager; Milena Jakimovska; Anna Jakubowska; Wolfgang Janni; Rudolf Kaaks; Daehee Kang; Pooja Middha Kapoor; Cari M Kitahara; Stella Koutros; Peter Kraft; Vessela N Kristensen; James V Lacey; Diether Lambrechts; Loic Le Marchand; Jingmei Li; Annika Lindblom; Jan Lubiński; Michael Lush; Arto Mannermaa; Mehdi Manoochehri; Sara Margolin; Shivaani Mariapun; Keitaro Matsuo; Dimitrios Mavroudis; Roger L Milne; Taru A Muranen; William G Newman; Dong-Young Noh; Børge G Nordestgaard; Nadia Obi; Andrew F Olshan; Håkan Olsson; Tjoung-Won Park-Simon; Christos Petridis; Paul D P Pharoah; Dijana Plaseska-Karanfilska; Nadege Presneau; Muhammad U Rashid; Gad Rennert; Hedy S Rennert; Valerie Rhenius; Atocha Romero; Emmanouil Saloustros; Elinor J Sawyer; Andreas Schneeweiss; Lukas Schwentner; Christopher Scott; Mitul Shah; Chen-Yang Shen; Xiao-Ou Shu; Melissa C Southey; Daniel O Stram; Rulla M Tamimi; William Tapper; Rob A E M Tollenaar; Ian Tomlinson; Diana Torres; Melissa A Troester; Thérèse Truong; Celine M Vachon; Qin Wang; Sophia S Wang; Justin A Williams; Robert Winqvist; Alicja Wolk; Anna H Wu; Keun-Young Yoo; Jyh-Cherng Yu; Wei Zheng; Argyrios Ziogas; Xiaohong R Yang; A Heather Eliassen; Michelle D Holmes; Montserrat García-Closas; Soo Hwang Teo Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-01-26 Impact factor: 4.090
Authors: Cindy K Blair; Charles L Wiggins; Andrea M Nibbe; Curt B Storlie; Eric R Prossnitz; Melanie Royce; Lesley C Lomo; Deirdre A Hill Journal: NPJ Breast Cancer Date: 2019-10-02
Authors: Fausto Petrelli; Alessio Cortellini; Alice Indini; Gianluca Tomasello; Michele Ghidini; Olga Nigro; Massimiliano Salati; Lorenzo Dottorini; Alessandro Iaculli; Antonio Varricchio; Valentina Rampulla; Sandro Barni; Mary Cabiddu; Antonio Bossi; Antonio Ghidini; Alberto Zaniboni Journal: JAMA Netw Open Date: 2021-03-01
Authors: Mustapha Abubakar; Hyuna Sung; Devi Bcr; Jennifer Guida; Tieng Swee Tang; Ruth M Pfeiffer; Xiaohong R Yang Journal: Breast Cancer Res Date: 2018-09-18 Impact factor: 6.466
Authors: Trygve Lofterød; Elin S Mortensen; Hawa Nalwoga; Tom Wilsgaard; Hanne Frydenberg; Terje Risberg; Anne Elise Eggen; Anne McTiernan; Sura Aziz; Erik A Wist; Andreas Stensvold; Jon B Reitan; Lars A Akslen; Inger Thune Journal: BMC Cancer Date: 2018-06-15 Impact factor: 4.430